Director - Pippa Anderson BSc, MSc

Pippa has an MSc in Quantitative and Economic Methods in Health Care from City University. Pippa’s research and consulting experience is in health economics and outcomes research. Her research expertise covers healthcare landscape assessment, measurement and valuation of health, international health care policy (as it relates to health technology assessment), funding, uptake and reimbursement of health technologies and in undertaking research and economic evaluation using observational data.  Her current research is focussed on the use of economic evidence by health care decision makers. 

Prior to coming to Swansea Centre for Health Economics at Swansea University, Pippa established Fourth Hurdle Consulting, a health economics consultancy, together with David Grant and Adam Lloyd.  Pippa has over thirty years experience in the health technology business, with expertise in sales, clinical research and consulting; and over seventeen years in health economics and outcomes research giving her considerable depth of experience. Her project leadership is supported by her many years of implementing robust project management practices.  Having ensured the successful integration of Fourth Hurdle into IMS HEOR in 2008, Pippa is now currently fulfilling a long held ambition to complete a PhD in Health Economics - based at the Swansea Centre for Health Economics at Swansea University. 

For six years to 2006, Pippa was a joint module leader for the Health Economics and Outcomes Research module of the MSc in Clinical Research based at John Moores University Liverpool.  She currently teaches a module of health economics and outcomes research to masters level students at Swansea University and Cranfield University. She also regularly presents on the use of health economics and outcomes research, at conferences for professionals in the health technology industry.

Pippa also acts as a deputy Health Economist for the All Wales Medicines Strategy Group and as a health economicst for the associated New Medicines Group.